Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology. The article reports a systematic analysis of the antibody responses to COVID-19 vaccination in cancer patients. This analysis … Read More

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study (ClinicalTrials.gov Identifier: NCT04708340 … Read More

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Reven’s lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients … Read More

Reven’s Co-Founder Michael Volk Appears on Cheddar News

Yesterday co-founder Michael Volk appeared on Cheddar News (40 million pay-tv households) to discuss the future of medicine. In this national broadcasted interview, Mr. Volk shared the company’s goals to bring their flagship platform drug Rejuveinix (RJX) to market. … Read More

Cheddar News Interview with Michael Volk

Michael Volk joins Cheddar News to discuss Reven Pharmaceuticals and RJX. … Read More

Reven Pharmaceuticals Reports A Promising Second Generation Formulation Of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX)

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Biomedicine and Pharmacotherapy.   In this new publication, Reven Pharmaceuticals team reports positive results regarding the safety and preclinical efficacy of a second generation formulation of its lead anti-sepsis drug candidate Rejuveinix (RJX).  … Read More

Reven Announces New Chief Operating Officer

Reven is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately. Mr. Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company’s flagship platform drug Rejuveinix (RJX) to market … Read More

Reven Holdings Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-risk COVID-19

Reven today announced that the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients (ClinicalTrials.gov Identifier:  NCT04708340 … Read More

Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer

Reven has launched its translational oncology program as a new drug discovery and development initiative that is aimed at changing the therapeutic landscape for difficult-to-treat forms of cancer. The overarching goal of this program is to treat cancer patients more effectively by altering the immediate surroundings of their tumor tissue, also known as the tumor microenvironment (TME). … Read More

Reven 2020YE Shareholder Update

We are happy to share the progress of Reven Holdings, Inc. (“Reven”) for the 2020 year. Despite an unprecedented global pandemic, 2020 was another year filled with major milestones for the company … Read More

Reven Pharmaceuticals Reports Positive Results Regarding the Clinical Safety and Preclinical Efficacy of its COVID-19 Drug Candidate Rejuveinix (RJX)

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology.  In this new publication, the Reven Pharmaceuticals team reports positive results regarding the clinical safety and preclinical efficacy … Read More

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

Reven today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and his academic collaborators in the medical journal, Frontiers in Nutrition … Read More

Reven Pharmaceuticals Wins FDA Approval of its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)

Reven today announced that the U.S Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application in connection with its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) as a potential treatment for COVID-19 patients … Read More

Reven Strengthens its Clinical Team with Three New Members

Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project … Read More

Reven Selects‌ E-Clinical Services‌ Provider‌ DSG for Clinical Data Management Services

Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. … Read More